LinusBio is a patient-centric, breakthrough science precision exposome medicine company headquartered in New York, NY. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/12/23 | $16,000,000 | Series A |
Bow Capital Divergent Investments Gillian Sandler GreatPoint Ventures Nicole Shanahan Sanford Robertson The David Bellet Family Office | undisclosed |
